Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
企業コードBNGO
会社名Bionano Genomics Inc
上場日Aug 01, 2018
最高経営責任者「CEO」Dr. R. Erik Holmlin, Ph.D.
従業員数98
証券種類Ordinary Share
決算期末Aug 01
本社所在地9540 Towne Centre Drive
都市SAN DIEGO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号92121
電話番号18588887600
ウェブサイトhttps://bionano.com/
企業コードBNGO
上場日Aug 01, 2018
最高経営責任者「CEO」Dr. R. Erik Holmlin, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし